These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 38490294)

  • 1. Unleashing the Potential of Oral Deliverable Nanomedicine in the Treatment of Inflammatory Bowel Disease.
    Yang C; Sharma K; Mow RJ; Bolay E; Srinivasan A; Merlin D
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101333. PubMed ID: 38490294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease.
    Li DF; Yang MF; Xu HM; Zhu MZ; Zhang Y; Tian CM; Nie YQ; Wang JY; Liang YJ; Yao J; Wang LS
    J Mater Chem B; 2022 Aug; 10(31):5853-5872. PubMed ID: 35876136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
    Yang C; Merlin D
    Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of nanomedicine in optimising the treatment of inflammatory bowel disease.
    Mohan LJ; Daly JS; Ryan BM; Ramtoola Z
    Scand J Gastroenterol; 2019 Jan; 54(1):18-26. PubMed ID: 30678499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease.
    Zhang Y; Thanou M; Vllasaliu D
    Eur J Pharm Biopharm; 2020 Oct; 155():128-138. PubMed ID: 32853696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease.
    Chen F; Liu Q; Xiong Y; Xu L
    Int J Nanomedicine; 2021; 16():4225-4237. PubMed ID: 34188471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.
    Hua S; Marks E; Schneider JJ; Keely S
    Nanomedicine; 2015 Jul; 11(5):1117-32. PubMed ID: 25784453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment.
    Gao J; Li J; Luo Z; Wang H; Ma Z
    Drug Des Devel Ther; 2024; 18():2921-2949. PubMed ID: 39055164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinspired and bioderived nanomedicine for inflammatory bowel disease.
    Gazzi R; Gelli R; Aleandri S; Carone M; Luciani P
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(4):e1986. PubMed ID: 39140489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine-mediated drug delivery for potential treatment of inflammatory bowel disease: a narrative review.
    Ardekani ZM; Lorenzo-Leal AL; Bach H
    Nanomedicine (Lond); 2024 Jan; 19(2):163-179. PubMed ID: 38284393
    [No Abstract]   [Full Text] [Related]  

  • 11. Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances.
    Hu S; Zhao R; Xu Y; Gu Z; Zhu B; Hu J
    J Mater Chem B; 2023 Dec; 12(1):13-38. PubMed ID: 38018424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Lehr CM; Fischer D; Stallmach A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):578-86. PubMed ID: 24084650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases.
    Zu M; Ma Y; Cannup B; Xie D; Jung Y; Zhang J; Yang C; Gao F; Merlin D; Xiao B
    Adv Drug Deliv Rev; 2021 Sep; 176():113887. PubMed ID: 34314785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulus-responsive drug delivery nanoplatforms for inflammatory bowel disease therapy.
    Long J; Liang X; Ao Z; Tang X; Li C; Yan K; Yu X; Wan Y; Li Y; Li C; Zhou M
    Acta Biomater; 2024 Oct; 188():27-47. PubMed ID: 39265673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral infliximab nanomedicines for targeted treatment of inflammatory bowel diseases.
    Mohan LJ; Daly JS; Ryan BM; Ramtoola Z
    Eur J Pharm Sci; 2023 Apr; 183():106379. PubMed ID: 36646154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.
    Xiao B; Merlin D
    Expert Opin Drug Deliv; 2012 Nov; 9(11):1393-407. PubMed ID: 23036075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Nanotechnologies and Microbiome Engineering for the Treatment of Inflammatory Bowel Disease.
    Abed OA; Attlassy Y; Xu J; Han K; Moon JJ
    Mol Pharm; 2022 Dec; 19(12):4393-4410. PubMed ID: 35878420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease.
    Zeeshan M; Ali H; Khan S; Khan SA; Weigmann B
    Int J Pharm; 2019 Mar; 558():201-214. PubMed ID: 30615925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
    Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
    Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An oral polyphenol host-guest nanoparticle for targeted therapy of inflammatory bowel disease.
    Zhang C; Zeng F; Fan Z; He Z; Tai L; Peng Q; Zhang Y; Chao Z; Jiang W; Jia L; Han L
    Acta Biomater; 2023 Oct; 169():422-433. PubMed ID: 37597682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.